Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gilead Sciences Approved to Market HCV Drug in China

publication date: Sep 25, 2017

Gilead Sciences of the US received CFDA approval for Sovaldi®, its once-daily oral treatment for chronic hepatitis C with ribavirin and/or interferon. Last year, Gilead began building a China commercial operation in Shanghai in preparation for the approval. The Shanghai office joins Gilead's regulatory team in Beijing, a chemical manufacturing outsourcing group in Shanghai, and a new manufacturing facility under construction in Hangzhou, the company's first plant outside the US. Gilead must still address the issue of Sovaldi's price in China: in the US, a three-month treatment regimen costs close to $100,000. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital